Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler.
Health and Human Services Secretary Robert F. Kennedy Jr. held a regenerative medicine roundtable on March 5.
Since rumors of this possible meeting began circulating, observers have been waiting anxiously for more information. It’s been seen as a likely first clear (or at least clearer) signal of how Kennedy might try to push the FDA to reduce oversight of cell therapies, particularly adult stem cells sold by unproven clinics. His now-famous October post on X claiming the FDA was suppressing good things like stem cells and peptides left many in the biomedical sciences scratching their heads about what he meant.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
